Eli Lilly and Company (LLY)
Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Eli Lilly Q3 earnings and revenue top estimates, boosted by weight loss drug demand
Eli Lilly and Co (NYSE:LLY) on Thursday reported third quarter 2025 financial results that handily beat Wall Street forecasts, as the company continued to see strong demand for its weight loss drug Zepbound and diabetes treatment Mounjaro. The pharmaceutical giant's revenue for the quarter rose 54% year over year to $17.60 billion, surpassing the analyst consensus estimate of $16.01 billion, according to data provided by LSEG.
Eli Lilly Blows Away Q3 Earnings Expectations
Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded expectations while raising full-year guidance.
20% Upside For Eli Lilly Stock?
Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli Lilly recently announced a significant partnership with Walmart to sell its popular weight-loss drug, Zepbound, at a discounted retail price through Walmart pharmacies.
Eli Lilly (LLY) Q3 Earnings and Revenues Surpass Estimates
Eli Lilly (LLY) came out with quarterly earnings of $7.02 per share, beating the Zacks Consensus Estimate of $6.02 per share. This compares to earnings of $1.18 per share a year ago.
Eli Lilly to invest $1.2 billion in Puerto Rico as part of US manufacturing push
Eli Lilly said on Wednesday it will invest more than $1.2 billion to expand its manufacturing site in Puerto Rico, as the drugmaker looks to increase its U.S. production capacity to hedge against potential tariffs.
In Lilly vs Novo obesity drug battle, Trump price talks grab focus
As obesity drug heavyweights Eli Lilly and Novo Nordisk gear up to release results for the third quarter, investors are looking elsewhere: high-stakes price talks with U.S. President Donald Trump.
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.
Is It Worth Investing in Lilly (LLY) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
LLY Stock To $1,100?
Eli Lilly (LLY) shares have surged by 16% over the last month and are currently priced at $825. U.S. pharmaceutical stocks have done well of late, as large drugmakers such as Pfizer and AstraZeneca signed drug pricing agreements with the Trump Administration to cut prescription drug prices and boost domestic manufacturing investments.
Eli Lilly: Is Another Monster Quarter Coming
October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound and Mounjaro. Since my article was published on September 8, Eli Lilly's stock price has risen by 13.1%. On October 24th, Eli Lilly surprised me by announcing its acquisition of Adverum Biotechnologies, a developer of gene therapies for the treatment of ocular diseases, for up to $261.7 million.
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.
